Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILLUMINATE-A: Lumasiran in Children and Adults with Primary Hyperoxaluria Type 1
2018-001981-40Phase 3Unknown
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Aug 2018
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Primary Hyperoxaluria Type 1 (PH1) and hyperoxaluria comparing Lumasiran with Placebo (2 arms). Primary endpoint: Percent change in 24-hour urinary oxalate excretion from baseline to Month 6. Status: unknown.
02
Drugs
lumasiran
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)hyperoxaluria
Beyond the preview
Go deeper on 2018-001981-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001981-40.